Podcasts about Bellini

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, shot live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the latest major trial results like CONNECT, TRIUMPH, and TRANSCEND.To begin the episode, Isaacs and Bellini, discuss major highlights from ADA Scientific Sessions, focusing first on the landmark CONNECT trial evaluating continuous glucose monitoring (CGM) in people with type 2 diabetes who are not treated with insulin. They reflect on the evolution of CGM technology, from its early use primarily in type 1 diabetes to its expanding role in type 2 diabetes management, and explain why this trial represents an important step forward for patients who have historically had limited access to CGM.The hosts review the randomized controlled trial findings, emphasizing the significant improvements in glycemic outcomes, including a 1.6% reduction in A1c from baseline and an approximately 0.9% greater reduction compared with standard care. They also highlight the increase in time in range, with participants using CGM achieving roughly five additional hours per day in target glucose range. The magnitude of these findings is discussed as a practice-changing development, with the potential to influence future clinical guidelines and strengthen recommendations for CGM use among individuals with type 2 diabetes who are not using insulin.The discussion also explores the broader implications of the CONNECT trial for healthcare access and insurance coverage. The hosts note that randomized controlled trial evidence has historically played a key role in shaping standards of care and payer decisions, and they suggest that these results may help support wider adoption of CGM by demonstrating meaningful improvements in glucose control and patient outcomes.The conversation then shifts to emerging pharmacologic advances, with a focus on retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon pathways. The hosts discuss new data showing substantial metabolic benefits in people with type 2 diabetes, including up to 17% weight reduction and nearly 2% A1c lowering. They highlight how these findings represent a major advancement in diabetes and obesity treatment, particularly as clinicians continue to see increasingly powerful effects from next-generation incretin-based therapies.Isaacs and Bellini explore how these therapies may reshape treatment strategies by allowing clinicians to tailor medication choices based on individual patient needs and goals. They discuss the importance of considering both glucose lowering and weight reduction effects, recognizing that some patients may benefit from significant weight loss while others may require a more balanced approach focused primarily on glycemic improvement.The hosts also address important unanswered questions surrounding the use of highly effective weight-loss medications, including appropriate treatment targets, the limitations of BMI as a measure, and the importance of preserving muscle mass and overall function. They emphasize the need to consider body composition, physical activity, resistance training, and patient characteristics—particularly in older adults or those at risk for frailty—when developing long-term treatment plans.The episode concludes with a reflection on the rapidly evolving landscape of diabetes care. The hosts highlight how advances in CGM technology and novel metabolic therapies are creating new opportunities to improve outcomes, personalize treatment approaches, and redefine the future management of people living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this special episode, shot live at the American Diabetes Association (ADA) Scientific Sessions 2026 in Ner Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Amit Gupta, MBBS, DNB, diabetologist, executive director of the Global Metabolic Health Alliance, and chair of the International Diabetes Federation (IDF) Education Committee, to discuss the state of diabetes care and treatment in India compared to the US.To begin the episode, Gupta introduces the mission of the IDF, highlighting its role as a worldwide federation of scientific societies and patient organizations focused on improving diabetes education, policy, advocacy, and access to care. The conversation explores how diabetes management differs across regions, emphasizing that while the underlying disease mechanisms and available therapies may be similar, access to medications, technologies, healthcare infrastructure, and education varies significantly between countries.Gupta discusses the impact of semaglutide becoming available as a generic therapy in India following patent expiration, describing how reduced costs have improved access to a medication previously limited by affordability barriers. The group considers how increased availability of GLP-1 receptor agonists may transform diabetes and obesity management, while also emphasizing that pharmacologic therapies alone cannot address the global metabolic health crisis. Gupta notes the importance of maintaining focus on long-term lifestyle changes, including nutrition, physical activity, and sustainable weight management, as essential components of comprehensive care.The discussion then shifts to diabetes education and the need for more individualized, patient-centered approaches. Gupta highlights that education must be adapted to regional and cultural contexts, explaining that the challenges faced by a person with diabetes in the United States, Africa, India, or other parts of the world may differ substantially, even though diabetes distress and the burden of daily decision-making are shared experiences. He emphasizes that access to technology, such as continuous glucose monitoring, does not eliminate the need for education and support.Isaacs, Bellini, and Gupta also address the growing challenge of misinformation online and the role of healthcare professionals in helping patients navigate unreliable sources of health information. Gupta explains that clinicians must approach misinformation constructively by providing evidence-based guidance rather than simply dismissing patients' beliefs, reinforcing the importance of translating scientific evidence into practical recommendations that patients can incorporate into their daily lives.The group further examines disparities in the availability of diabetes educators worldwide. Gupta notes that while some regions have established professional pathways for diabetes care and education specialists, many areas lack standardized training, recognition, or policy support to sustain these roles. He stresses that building effective diabetes education systems requires collaboration with policymakers to demonstrate the long-term benefits of structured education programs.The episode concludes with Gupta discussing his work developing a global consensus framework on lifestyle as the foundation of metabolic health. The conversation reinforces that advances in medications and technology must be paired with equitable access, effective education, and sustainable lifestyle interventions to reduce the global burden of diabetes and improve outcomes for people living with metabolic conditions.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Gupta reports disclosures with Lilly, Abbott Diabetes, and the International Diabetes Federation.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Trang Ly, PhD, MBBS, senior vice president and Chief Medical Officer at Insulet, to discuss the continued evolution of automated insulin delivery (AID) technology and emerging developments across the Omnipod platform. To begin the episode, Ly first reviews updates to Omnipod 5, focusing on enhancements aimed at increasing time in automated mode and improving glucose management. She explains that user feedback identified opportunities to support lower glucose targets and reduce interruptions related to system alerts. Data from real-world evidence and computer simulations suggest that lowering the glucose target from 110 to 100 mg/dL may lead to meaningful improvements in time in range and time in tight range without increasing hypoglycemia risk.The group discusses early clinical experience with these enhancements, including findings from users who transitioned to the updated system. Ly highlights that even a highly engaged population already using lower targets experienced additional improvements, including a 2% increase in time in range and a 5% increase in time in tight range over a short period of use. The conversation emphasizes the importance of making these improvements broadly available rather than waiting for routine follow-up visits, particularly given the potential benefits without additional safety concerns.The discussion then turns to Omnipod 6, with Ly sharing newly presented clinical trial data evaluating the next-generation system. She describes the study design, which enrolled users already achieving strong glycemic control on Omnipod 5 and assessed whether further intensification through algorithm improvements could safely provide additional benefits. The results demonstrated a 4% improvement in time in range and up to a 7% increase in time in tight range, with particularly notable improvements among individuals with type 1 diabetes aged 14 years and older.Ly explains that Omnipod 6 builds on previous technology through changes to the core algorithm, allowing the system to deliver more insulin when users do not bolus consistently. The panel explores how this approach may reduce the burden of diabetes management by allowing the algorithm to take on more responsibility while maintaining glycemic control. They discuss the potential psychological benefits of reducing the daily demands placed on people with diabetes, especially as sensor accuracy and automation continue to improve.The conversation also highlights future opportunities for AID in type 2 diabetes. Ly shares early feasibility data from a fully closed-loop system designed specifically for individuals with type 2 diabetes, emphasizing its simplified approach without requiring traditional pump programming or meal bolusing. In this study, participants experienced improvements in time in range, demonstrating the potential for automated insulin delivery to reach broader populations.Isaacs and Bellini discuss the need to reconsider barriers to insulin pump adoption in type 2 diabetes and recognize AID as an accessible option for patients who may benefit. Ly emphasizes that technology should support people across different levels of engagement, offering both highly customizable systems for those seeking intensive management and simpler automated approaches for those looking to reduce daily treatment demands.The episode concludes with a discussion of the future of diabetes technology, including improved connectivity, expanded device flexibility, and continued integration with complementary therapies such as GLP-1 receptor agonists. Ly underscores that innovation should not only improve clinical outcomes but also reduce the burden of care, allowing people with diabetes to spend less time managing their condition and more time living their lives.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Ly reports a disclosure with Insulet.References1: Insulet. Insulet Reveals New Data Supporting Breakthrough Omnipod 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care. June 6, 2026. Accessed June 7, 2026. https://investors.insulet.com/news/news-details/2026/Insulet-Reveals-New-Data-Supporting-Breakthrough-Omnipod-6-and-Fully-Closed-Loop-AID-Systems-Designed-to-Improve-Outcomes-Reduce-Effort-and-Unlock-Barriers-to-Care/default.aspx

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Ketan Dhatariya, MD, PhD, MS, consultant physician at Norfolk and Norwich University Hospitals, to discuss the evolving landscape of diabetes care, technology access, and clinical implementation. To begin the episode, Dhatariya shares his perspective on the challenges facing diabetologists, including workforce pressures, specialist training, and the difficulty of translating rapidly expanding diabetes guidelines and innovations into everyday clinical practice. The conversation then shifts to the differences between healthcare systems and how those structures influence access to diabetes therapies. Dhatariya discusses the UK's publicly funded healthcare model and the ongoing challenge of balancing the cost of emerging medications and technologies with their long-term benefits. He highlights the importance of demonstrating that investments in diabetes care today can reduce complications and healthcare costs in the future.Dhatariya then reviews the progress of continuous glucose monitoring (CGM) and automated insulin delivery (AID) adoption in the UK. He explains that CGM use among people with type 1 diabetes has become widespread, particularly among children, and that access to closed-loop systems continues to expand through structured implementation plans. He emphasizes the meaningful improvements these technologies have provided, including better glycemic outcomes among children and pregnant individuals, who may experience significant benefits from improved glucose management.The discussion explores how diabetes technology can support people with different lifestyles and challenges, while challenging assumptions about which patients may benefit most from advanced therapies. Dhatariya highlights that CGM and AID can provide valuable support for individuals who may struggle with traditional insulin management, while also emphasizing the need for appropriate education and follow-up to ensure safe and effective use.The group also discusses CGM use in type 2 diabetes and the growing evidence supporting broader access. Dhatariya explains that adoption has been slower because of the larger population affected by type 2 diabetes but notes emerging data suggesting CGM may help reduce complications, hospitalizations, and long-term healthcare costs. He describes the impact of seeing real-time glucose data, explaining how personal experience with CGM can help people better understand the relationship between food, behavior, and glucose patterns.The conversation then turns to access to GLP-1 receptor agonists in the UK and how healthcare systems determine eligibility for newer therapies. Dhatariya discusses the role of national guidance and health economic evaluations in balancing access, affordability, and sustainability. He highlights how improving obesity-related disease management may have broader benefits, including helping reduce the burden of diabetes, cardiovascular disease, and other chronic conditions.The episode also explores inpatient diabetes care and the increasing presence of diabetes technology in hospital settings. Dhatariya discusses guidance developed by the Joint British Diabetes Societies for Inpatient Care to help clinicians safely manage patients admitted while using CGM, insulin pumps, and AID systems. He emphasizes that devices should not automatically be removed and that patients may be able to continue using technology when they are well enough and capable of managing their systems.Finally, Dhatariya discusses the importance of structured diabetes education, including the DAFNE (Dose Adjustment For Normal Eating) program, which teaches carbohydrate counting, insulin adjustment, and self-management skills. He emphasizes that as diabetes technology becomes more advanced, education remains essential for both patients and clinicians. The episode concludes with a discussion of the need for continued advocacy, specialist care, and equitable access to ensure people with diabetes can benefit from ongoing advances in diabetes technology.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Dhatariya reports disclosures with AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded on-site at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Dr. Eugene Wright Jr., MD, the principal of Wright Health Care Solutions and a consulting associate in the department of medicine at Duke University Medical Center, to discuss the development of the ADA scientific statement on diabetes technology implementation in primary care. To begin the episode, Wright reflects on his career as an internist caring for patients with diabetes across diverse settings, including underserved communities where patients often faced significant barriers to accessing care. He describes how his experiences challenged assumptions about which patients would benefit from diabetes technology, noting that many under-resourced patients demonstrated strong engagement and improved self-management when given access to tools such as continuous glucose monitoring (CGM).The discussion focuses on the origins of the ADA scientific statement, which emerged from efforts to identify and overcome barriers limiting the adoption of diabetes technology in primary care. Wright explains that while diabetes technology has demonstrated significant benefits in improving outcomes and patient behaviors, implementation has remained slow in the settings where most people with diabetes receive care. The statement brought together key stakeholders, including clinicians, pharmacists, diabetes care and education specialists, patient representatives, and other experts, to develop practical strategies addressing policy, insurance, workflow, and clinical challenges.Isaacs, Bellini, and Wright explore how CGM can be successfully integrated into primary care by shifting the focus from simply providing access to using data effectively. Wright emphasizes that CGM and ambulatory glucose profile (AGP) reports allow clinicians to transform complex glucose data into actionable insights, helping identify patterns that may not be captured through A1C measurements or traditional glucose monitoring. The group discusses how CGM enables clinicians to ask better questions, uncover barriers to treatment, and engage patients in collaborative conversations without judgment.The hosts highlight the importance of building sustainable workflows, including preparing AGP reports before visits, assigning responsibilities across the care team, and identifying technology champions within practices. Wright explains that successful implementation requires recognizing the unique needs and resources of each primary care setting rather than applying a single model. They discuss the role of telehealth, clinical pharmacists, medical assistants, and other team members in supporting CGM initiation, interpretation, and ongoing management. The conversation also addresses how partnerships with technology manufacturers can simplify onboarding, training, troubleshooting, and patient support.The discussion then expands to insulin pumps and automated insulin delivery systems, with the group noting how advances in technology have reduced complexity and made these therapies more accessible for people with type 2 diabetes. Wright describes how newer systems can help reduce the daily burden of diabetes management by automating adjustments and supporting patients in achieving their goals. The hosts emphasize that diabetes care should move beyond focusing only on glucose metrics and instead consider the lived experience of patients, including the constant decision-making and emotional burden associated with managing diabetes.The episode concludes with a broader call to action for expanding access to diabetes technology across all healthcare settings. Wright emphasizes that many patients do not have access to endocrinology care but still deserve the benefits of modern diabetes tools. The scientific statement represents the beginning of an ongoing effort to improve implementation, strengthen collaboration among stakeholders, and ensure that diabetes technology reaches all patients who can benefit from it.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Wright Jr. reports disclosures with Abbott Diabetes, Bayer AG, Boehringer Ingelheim, Lilly, and Sanofi.ReferencesSection 7: Diabetes technology. Diabetes Obesity and Cardiometabolic CARE. Published online March 23, 2026. doi:10.2337/doc26-a007

01 - Andrewboy & Szecsei feat Kinga Peterfy - Kiskece 2016 (Strong R. Intro Version) 02 - Jamie Woon - Shoulda (Purebeat Special After Remix) 03 - Lee Cabrera & Thomas Gold - Shake It (Move A Little Closer) (Jackwell Remix) 04 - Saby Davis x Eiffel 65 - Return Of The Blue (Jackwell & Szecsei Mashup) 05 - G & G - Personal Jesus (Jackwell & Szecsei Remix) 06 - Rico x Miss Mood - Vihar (Dj Free & Purebeat Remix) 07 - Endor - Pump It Up (TAZI Edit) 08 - Tomcraft - Like A Roller (Jackwell & Field Bootleg) 09 - Radio Slave feat Danton Eeprom - Grindhouse (Johnes & Szecsei 2016 Edit) 10 - Mario - Kimaradás (Darius x Sunshine State Remix) 11 - Gorgon City feat Katy Menditta - Imagination (Jackwell Bootleg) 12 - Diplo feat SIDEPIECE - On My Mind (Jackwell Bootleg) 13 - Gala - Freed from Desire (Orkestrated Re-Rub) 14 - Eminem x Inndrive - Without Me (Jackwell Edit) 15 - Shouse - Won't Forget You (Jackwell Bootleg 2.0) 16 - FISHER - Losing It (Eryk Gee Edit) 17 - Tube & Berger feat Juliet Sikora - Set It Off (Come On Now) (Purebeat Special After Remix 2014) 18 - Offer Nissim feat Maya - First Time (Jackwell & Field Bootleg) 19 - A-Studio feat Polina - S.O.S. 2024 (B-Sensual Mix) 20 - Run DMC vs Jason Nevins - It's Like That (Raxon vs B-Sensual Mix) 21 - Fedde Le Grand & Funkerman feat Dorothy & Andy Sherman - 3 Minutes To Explain (Original Mix) 22 - D. Ramirez & Mark Knight & Underworld - Downpipe (Original Club Mix) 23 - Ron Carroll - Bump To This (Muzzaik Remix) 24 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 25 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 26 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 27 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 28 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 29 - Pogány Induló x Parno Graszt - Székelykapu (B00ST Hypertechno Remix) 30 - 50 Cent - In Da Club (RobxDan Extended Remix) 31 - Sebastian Bronk - Everytime We Touch (Extended) 32 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 33 - Alice Deejay - Better Off Alone (Olly James Techno Rework) 34 - MO-DO - Eins Zwei Polizei (Jaydan Wolf & YuB Edit) 35 - Bassjackers - Around The World (La La La La La) (Extended Mix) 36 - DJ Kuba & Ne!tan x Terri B! with DJ Terry - Mr. Vain (Festival Cut) 37 - R3SPAWN & Nia Mousai - Bad Romance (Extended Mix) 38 - Geri Halliwell - It's Raining Men (YuB & MAZZOCCHI Techno Remix) 39 - Sebastian Bronk - L'Amour Toujours (Extended Version) 40 - Szecsei x Darwin feat Red Luna - My My My (Original Mix) 41 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Remix) 42 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Bootleg) 43 - Martin Books - Liquid (Jackwell Szecsei Edit) 44 - Karen Harding - Say Something (Purebeat Special After Edit) 45 - Andrewboy feat Timi Szegedi - No More Silence (Jackwell & Szecsei Remix) 46 - Strong R. X Szecsei - Érezd A Ritmust (Extended Mix)

Et après on a bu des Bellini en terrasse. Merci à Jaume Balagueró, Nicolas Landais, UFO.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent FDA approval of MannKind's inhaled insulin Afrezza for pediatric patients aged 6 years and older with both type 1 and type 2 diabetes, describing the decision as a major milestone in diabetes therapeutics and the first expansion of the therapy beyond adults. The episode centers on the clinical implications of the approval, the pharmacologic advantages of inhaled insulin, and the practical considerations surrounding implementation in pediatric care settings.The hosts review findings from the INHALE-1 trial, which enrolled 230 pediatric participants aged 4 to 17 years and compared inhaled insulin used alongside basal insulin with standard multiple daily injection (MDI) therapy over 56 weeks. Bellini emphasizes that the study achieved its primary objective of demonstrating glycemic outcomes comparable to traditional insulin regimens, noting that insulin studies are generally designed to establish equivalence rather than superiority. Beyond similar glycemic control, the hosts highlight several clinically meaningful secondary observations, including stable BMI among participants receiving inhaled insulin compared with weight gain in the MDI cohort, increased treatment satisfaction reported by both adolescents and parents of younger children, comparable hypoglycemia rates, and the absence of new safety concerns. Bellini also notes that no decline in lung function was observed among participants using inhaled insulin, despite historical concerns surrounding pulmonary safety with inhaled therapies.A major focus of the discussion is the physiologic pharmacokinetic profile of Afrezza, which Isaacs characterizes as the most physiologic insulin currently available. She explains that inhaled insulin demonstrates measurable activity within approximately 12 minutes, peaks within 35 to 45 minutes, and clears the bloodstream in roughly 90 minutes. The hosts contrast this with subcutaneous rapid-acting insulin analogs, including ultra-rapid formulations, which retain a prolonged “tail” of insulin activity that can increase hypoglycemia risk. Isaacs and Bellini suggest that the shorter duration of inhaled insulin may reduce the cycle of overtreating hypoglycemia and subsequent rebound hyperglycemia, thereby potentially contributing to the absence of weight gain observed in the trial. Bellini further emphasizes that the rapid onset and offset of inhaled insulin restore some of the flexibility and spontaneity often lost in intensive insulin therapy, particularly around meal dosing and correction strategies.The conversation also situates inhaled insulin within the broader framework of individualized diabetes management and the ADA Standards of Care. Isaacs stresses that the approval should not be viewed as competing with automated insulin delivery (AID) systems, but rather as expanding patient choice. The hosts discuss how inhaled insulin may be especially valuable for individuals who do not wish to wear insulin pumps, desire periodic breaks from technology, or want to reduce the burden of injections. Isaacs additionally highlights the growing prevalence of pediatric type 2 diabetes and notes that, despite advances in incretin-based therapies, many youth still require insulin therapy. In that context, the possibility of pairing inhaled mealtime insulin with emerging once-weekly basal insulin formulations and GLP-1 receptor agonists is presented as a potentially transformative strategy for minimizing injection burden.Bellini and Isaacs also address practical implementation challenges within school settings. Because inhaled insulin acts rapidly, Bellini notes that administration timing may need to shift from the nurse's office to the cafeteria environment to avoid hypoglycemia if meals are delayed. At the same time, both hosts recognize that the flexibility of postprandial dosing could offer advantages for children with inconsistent eating patterns or concerns about privacy surrounding insulin administration. They further discuss the utility of inhaled insulin for rapid glucose corrections, noting that additional doses can be administered far sooner than with traditional injected rapid-acting insulin.The episode concludes with discussion of anticipated affordability initiatives from MannKind Corporation, including bridge programs designed to improve early access and reduce financial barriers to therapy. Isaacs and Bellini commend the company's efforts to secure pediatric approval and express optimism that broader availability of inhaled insulin will expand individualized treatment options, improve patient satisfaction, and enhance quality of life for children and adolescents living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.References1: HOLDER

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss several major developments in diabetes technology and obesity therapeutics, beginning with Abbott's announcement that its dual glucose-ketone monitoring systems, Libre Duo and Libre Duo 10 Day, have received CE mark approval in Europe. The hosts describe the devices as the first continuous glucose-ketone monitors capable of simultaneously measuring glucose and ketone levels through a single wearable sensor, with real-time ketone monitoring intended to identify rising risk for diabetic ketoacidosis (DKA). Bellini explains the rationale for separate 15-day adult and 10-day pediatric sensors, noting higher sensor failure rates and greater activity levels in children. Both hosts emphasize the potential clinical significance of continuous ketone monitoring, particularly for individuals with type 1 diabetes (T1D) using insulin pumps, where interruptions in insulin delivery can rapidly precipitate DKA.The discussion further explores how continuous ketone monitoring may expand the safe use of SGLT2 inhibitors in people with T1D and other high-risk populations. Bellini highlights concerns surrounding euglycemic DKA associated with SGLT2 inhibitor therapy and suggests that continuous ketone data could help clinicians identify susceptible individuals earlier, potentially enabling safer and more individualized dosing strategies. Isaacs underscores the limitations of current ketone testing methods, particularly urine ketone testing, which she characterizes as outdated and insufficient for modern diabetes management. The hosts also review additional patient populations that may benefit from continuous ketone monitoring, including individuals with recurrent DKA, pediatric patients with highly variable glycemic patterns, and hospitalized patients at elevated risk for ketosis due to prolonged fasting or treatment interruptions.Isaacs and Bellini also consider practical questions surrounding implementation, including reimbursement, cost, workflow integration, and compatibility with automated insulin delivery systems. They discuss whether continuous ketone monitoring could eventually become standard of care in T1D and debate the broader implications of widespread ketone data availability, including potential consumer interest outside traditional diabetes populations. Both hosts stress the importance of prioritizing access for patients at highest risk for DKA while acknowledging that broader adoption could reshape diabetes monitoring paradigms similarly to the evolution of continuous glucose monitoring.The episode then turns to recent reports involving Dexcom sensors that were reportedly stolen after being removed from the manufacturing process for quality concerns. Bellini explains that some of the affected sensors may not have completed sterility and quality assurance procedures before entering secondary markets. The hosts caution clinicians to review affected lot numbers and encourage ongoing vigilance until additional information becomes available. They also discuss the challenges of communicating recalls and safety alerts directly to patients, particularly for users relying on standalone receivers that may not connect to cloud-based notification systems.Finally, Isaacs and Bellini review newly released topline results from the phase 3 TRIUMPH-1 trial evaluating retatrutide, Lilly's investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. Bellini summarizes findings demonstrating substantial weight reduction among adults with obesity or overweight without diabetes, including mean weight loss exceeding 28% at 80 weeks and continued weight reduction through 104 weeks without evidence of plateau. The hosts note that nearly half of participants achieved at least 30% weight loss, approaching outcomes historically associated with bariatric surgery. They also highlight low discontinuation rates and discuss the implications of future TRIUMPH studies evaluating retatrutide in patients with type 2 diabetes and cardiovascular disease. Isaacs concludes that the emerging data signal a transformative shift in obesity treatment, with pharmacologic therapies increasingly approaching surgical efficacy and potentially reshaping long-term obesity management strategies.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Jeffrey corrobora una filtración y anuncia unos lanzamientos recientes.¿Qué estoy usando hoy?:Mondu Stefanu (M) Parker Penman EmeraldTinteríasAnuncio: Platinum descatalogará la Curidas y la #3776 Century BENU Cocktail Hour (Mojito, Bellini, Pink Lady)Keyno Stationery no. 001 SerenityLAMY Safari Neon Pink y Neon YellowMonteverde Innova 2026 Color of the Year — Cloud DancerSailor 1911 REALO 18kTWSBI Eco Fluorite Purple con BronceTintería del capítulo: COCTELERÍA

01 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 02 - Sebastian Bronk - L'Amour Toujours (Extended Version) 03 - MO-DO - Eins Zwei Polizei (Jaydan Wolf & YuB Edit) 04 - DJ Kuba & Ne!tan x Terri B! with DJ Terry - Mr. Vain (Festival Cut) 05 - Geri Halliwell - It's Raining Men (YuB & MAZZOCCHI Techno Remix) 06 - Bassjackers - Around The World (La La La La La) (Extended Mix) 07 - SNAP - Rhythm Is A Dancer (LUSSO Bootleg) 08 - Ice Mc - Think About The Way (Kyros Remix) 09 - Eminem vs R3SPAWN - Without Me vs E (Josh Le Tissier Mashup) 10 - Joy Kitikonti x MC Goodgrip - Joyenergizer x Rocking with the Best (LUSSO Mashup Cut) 11 - R3SPAWN - No Good (Extended Mix) 12 - Usher - Yeah (NAEMS X Dirty Signal Bootleg Cut) 13 - LMFAO - Sexy & I Know It (Tazi & Beama Edit) 14 - Alice Deejay - Better Off Alone (Olly James Techno Rework) 15 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 16 - Sebastian Bronk - Everytime We Touch (Extended) 17 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 18 - Josh Le Tissier - Calabria (Techno Edit) 19 - Dirty Signal & Blink & Ezra Hazard - No Limit (Extended) 20 - Dr. Dre & Snoop Dogg - The Next Episode (Josh Le Tissier Techno Remix) 21 - Barthezz - On The Move (2ACES & Dirty Signal 2026 Edit Cut) 22 - Corona - The Rhythm Of The Night (Cosmic No1ze Techno Remix) 23 - Benny Benassi - Satisfaction (BEAUZ Hard Techno Remix) 24 - Soundlovers - Surrender (ENCR Remix) 25 - Gigi D'Agostino - Bla Bla Bla (Fahjah x Jesyka Nu Groove Remix) 26 - 50 Cent - In Da Club (RobxDan Extended Remix) 27 - La Bouche - Be My Lover (ThnderZ x Lupage x Teddy Cream RaveTok Cut) 28 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Bootleg)

01 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Intro Version) 02 - HADEN x Szecsei - Cherokee 2025 (Extended Remix) 03 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 04 - Dr. Dre & Snoop Dogg - The Next Episode (Josh Le Tissier Techno Remix) 05 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 06 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 07 - GORDO X Reinier Zonneveld X KAAZE - Loco Loco x Papi (Rudeejay & Da Brozz Bootleg) 08 - MilleniumKid x JBS - Vielleicht Vielleicht (Scotty Extended Mix) 09 - BEAUZ & Cassie Ann - Dame Un Grr (Extended Mix) 10 - Kato feat Jon - Turn The Lights Off (BMzk Remix) 11 - Jaden Bojsen & David Guetta - Let's Go (Scotty Extended Mix) 12 - 50 Cent - In Da Club (RobxDan Extended Remix) 13 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 14 - Travis Scott - FE!N (Rudeejay & Da Brozz Bootleg) 15 - Benny Benassi - Satisfaction (BEAUZ Hard Techno Remix) 16 - BEAUZ - Ocho (Extended Mix) 17 - Dirty Signal & Blink & Ezra Hazard - No Limit (Extended) 18 - Sebastian Bronk - Everytime We Touch (Extended) 19 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 20 - Eminem vs R3SPAWN - Without Me vs E (Josh Le Tissier Mashup) 21 - Usher - Yeah (NAEMS X Dirty Signal Bootleg Cut) 22 - Creeds - Push Up (Szecsei & Dante Edit)

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special in-studio episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reflect on major themes and anticipated developments ahead of the upcoming American Diabetes Association (ADA) Scientific Sessions 2026.The discussion opens with Bellini congratulating Isaacs on receiving the ADA Outstanding Educator in Diabetes Award, prompting a conversation centered on Isaacs' forthcoming presentation, “Behind Every Number Is a Story: Transforming Diabetes Care and Education through Technology and Human Connection.” Isaacs reflects on the rapid evolution of diabetes technology over the last decade, from limited continuous glucose monitoring (CGM) access and the emergence of early automated insulin delivery (AID) systems to the integration of artificial intelligence into diabetes care, while emphasizing that successful care remains grounded in human connection and individualized patient experiences.The hosts then preview several therapeutic areas expected to dominate discussion at ADA, particularly the expanding pipeline of incretin-based therapies. Bellini and Isaacs discuss growing excitement surrounding GLP-1, GIP, and glucagon receptor agonists, including anticipated data from triple agonist agents such as retatrutide and emerging oral therapies like orforglipron. They highlight the significance of improved weight-loss efficacy in people with type 2 diabetes (T2D), broader cardiometabolic applications, and the increasing importance of treatment accessibility and affordability. The conversation also explores the expanding role of these therapies in addressing cardiovascular disease, chronic kidney disease, sleep apnea, osteoarthritis, and other obesity-related comorbidities.Technology advancements represent another major focus of the episode. Isaacs and Bellini discuss new CGM-driven insulin titration tools, including Dexcom's Smart Basal feature, designed to address therapeutic inertia among people with T2D using basal insulin. They also examine the growing role of CGM in broader patient populations and discuss evolving ADA recommendations supporting CGM access for any individual likely to benefit from the technology. The hosts express particular enthusiasm for the anticipated arrival of continuous ketone monitoring, including dual glucose-ketone sensors, and consider how these devices may transform diabetic ketoacidosis prevention and patient education, particularly for individuals with type 1 diabetes (T1D).The conversation also highlights continued innovation in insulin delivery systems and connected diabetes devices. Isaacs and Bellini discuss progress toward fully closed-loop AID systems, including ongoing studies evaluating meal-unannounced insulin delivery in T2D. They review emerging insulin pump technologies from Medtronic, including updates to the MiniMed platform and the integration of connected insulin pen systems with real-time CGM data through the MiniMed Go app. The hosts emphasize the importance of preserving therapeutic choice for people who prefer injections over pump therapy or who seek temporary alternatives to wearable devices.Toward the conclusion of the episode, both hosts preview their own ADA presentations. Isaacs discusses an upcoming session on inhaled insulin that will use simulated patient scenarios to explore shared decision-making and individualized therapy selection. Bellini highlights her session focused on skin complications related to diabetes technologies, including allergic reactions and adhesive-related challenges that can interfere with sustained device use. Together, they underscore the importance of addressing practical barriers to technology adoption while continuing to expand therapeutic and technological options for people living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Episode: 1573 Donatello: Of his age or for all time?  Today, we ask: Of an age, or of all time?

How could we not check this film out? Collin has welcomed us all – to his wooden ways. Cosimo (Greendale Community College Alum, Luis Guzmán) gets locked up and learns about the perfect heist from his cellmate. He just needs to get out to do it. He confides in his gal pal Rosalind (Patricia Clarkson) which leads to everyone knowing and wanting a piece for themselves. This includes Pero (Sam Rockwell), Riley (William H. Macy), Leon (Isaiah Washington) and Toto (Michael Jeter). This makes Cosimo angry, and he has a lot to say about everyone's mothers. In the background, there's a bit of romance between Pero and Carmela (Jennifer Esposito). Will anyone care? George Clooney is even doing some stuff here. RTS knows when there's a real Bellini on the table. This isn't it. Jeremy considers being a Mullinski but the price has to be just right. La-Mar finds hidden treasures in the cookie jar. Collin has already given you everything. He has welcomed you. Isn't that enough for you? Don't let this turn into a real Kapuchnik. 

A cura di Paolo PellegriniVincenzo Bellini, La SonnambulaAmina (Orfanella), Joan SutherlandElvino (Ricco possidente), Nicolai GeddaIl Conte Rodolfo (Signore del villaggio), Ezio FlagelloLisa (Ostessa), Jeanette ScovottiTeresa (Mugnaia, madre adottiva di Amina), Lili ChookasianAlessio (Contadino), John MacurdyUn Notaio, Andrea VelisCoro e Orchestra del Metropolitan Opera House di New YorkSilvio Varviso, direttore

durée : 02:00:30 - Le 5/7 - par : Mathilde Munos - A 5h45 : Danielle Bellini, retraitée, fondatrice d'un lieu de résidence d'artistes. A 6h20 : Paul Tourret, directeur de l'ISEMAR, l'Institut Supérieur d'Économie Maritime. - réalisation : Elise Amchin, Joachim Taieb Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:05:26 - Le 5/7 - par : Mathilde Munos - Danielle Bellini, retraitée, fondatrice d'un lieu de résidence d'artiste. Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:05:26 - Les interviews d'Inter - par : Mathilde Munos - Danielle Bellini, retraitée, fondatrice d'un lieu de résidence d'artiste. Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:05:26 - Déjà debout - par : Mathilde Munos - Danielle Bellini, retraitée, fondatrice d'un lieu de résidence d'artiste. Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

01 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 02 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 03 - Dirty Signal & Blink & Ezra Hazard - No Limit (Extended) 04 - Dr. Dre & Snoop Dogg - The Next Episode (Josh Le Tissier Techno Remix) 05 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 06 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 07 - R3SPAWN & Nia Mousai - Bad Romance (Extended Mix) 08 - Ice Mc - Think About The Way (Kyros Remix) 09 - Usher - Yeah (NAEMS X Dirty Signal Bootleg Cut) 10 - Eminem vs R3SPAWN - Without Me vs E (Josh Le Tissier Mashup) 11 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 12 - 50 Cent - In Da Club (RobxDan Extended Remix) 13 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Remix) 14 - MilleniumKid x JBS - Vielleicht Vielleicht (Scotty Extended Mix) 15 - GORDO X Reinier Zonneveld X KAAZE - Loco Loco x Papi (Rudeejay & Da Brozz Bootleg) 16 - Kato feat Jon - Turn The Lights Off (BMzk Remix) 17 - MO-DO - Eins Zwei Polizei (Jaydan Wolf & YuB Edit) 18 - Sebastian Bronk - Everytime We Touch (Extended) 19 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 20 - Alice Deejay - Better Off Alone (Olly James Techno Rework) 21 - Pogány Induló x Parno Graszt - Székelykapu (B00ST Hypertechno Remix) 22 - HUNTRIX - Golden (Wukong & Skyray Mix) 23 - Szecsei x Darwin feat Red Luna - My My My (Original Mix) 24 - Sebastian Bronk - L'Amour Toujours (Extended Version) 25 - Bomfunk MC's - Freestyler (Matt Bukovski Cut) 26 - Endor - Pump It Up (SHU Remix Edit) 27 - Strong R. X Szecsei - Érezd A Ritmust (Short Mix) 28 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Bootleg) 29 - Andrewboy & Szecsei feat Kinga Peterfy - Kiskece 2016 (Strong R. Remix)

Adriana Maya sits down with Raissa Bellini for a candid conversation about moving from Italy to Miami, starting over, and building a name fast in adult entertainment and content creation. They get into ambition, attention, online fame, pressure, and what it really takes to grow a brand in a space that moves fast and judges hard. Raissa also opens up about the lifestyle behind the image and the mindset it takes to keep pushing forward.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a slew of advances in diabetes technology and treatments, starting with the US Food and Drug Administration (FDA)'s recent approval of the Tandem automated insulin delivery system for use during pregnancy in individuals with type 1 diabetes. The conversation centers on findings from the CIRCUIT trial, which demonstrated significant improvements in time in range among pregnant patients, a population historically challenging to manage because of stringent glycemic targets. Isaacs and Bellini review practical considerations from the study, including the use of continuous sleep mode to target tighter glucose ranges and proactive optimization of basal rates, correction factors, and carbohydrate ratios to improve outcomes. They emphasize that FDA approval now allows clinicians and manufacturers to openly discuss evidence-based best practices for pregnancy management using automated insulin delivery systems.The hosts also highlight the importance of clinician comfort with aggressive insulin automation during pregnancy, noting that increased basal modulation, suspensions, and automated adjustments should be expected as physiologic insulin needs fluctuate throughout gestation. Bellini stresses the importance of reducing patient burden while maintaining intensive glycemic management, tying this theme into Tandem's newly announced compatibility with the Dexcom G7 15-day sensor. Both hosts note strong patient enthusiasm for extending sensor wear time, framing reduced device maintenance as an important quality-of-life improvement even when the practical change appears modest.The discussion then shifts to immunotherapy in type 1 diabetes, focusing on the expanded approval of teplizumab to include children as young as 1 year old for delaying progression from stage 2 to stage 3 disease. Isaacs and Bellini underscore how broader eligibility may strengthen adoption of autoantibody screening among relatives of patients with type 1 diabetes. They review evidence showing that screening substantially lowers rates of diabetic ketoacidosis at diagnosis and discuss the broader clinical significance of delaying symptomatic disease onset, even when delays are shorter than the median duration reported in trials. The hosts note that many families value the possibility of a more gradual transition into insulin dependence, often requiring only minimal insulin therapy initially rather than presenting with severe metabolic decompensation.The conversation also addresses ongoing regulatory developments surrounding teplizumab for newly diagnosed stage 3 type 1 diabetes. Although the anticipated expedited review pathway has been withdrawn, the hosts remain optimistic about eventual approval, citing encouraging data and the growing role of precision medicine approaches in identifying patients most likely to benefit from immune intervention.To conclude the episode, Isaacs and Bellini examine a post hoc analysis from the SURMOUNT-5 trial comparing tirzepatide and semaglutide in adults with obesity and prediabetes. They discuss findings showing high rates of reversion to normoglycemia in both treatment groups, with tirzepatide demonstrating greater efficacy overall. The hosts frame these data within the broader movement to reconceptualize prediabetes as an earlier stage of type 2 diabetes and cardiovascular disease risk rather than a benign precursor state. They emphasize the potential value of earlier therapeutic intervention to prevent progression and reduce long-term cardiometabolic complications while also acknowledging the importance of maintaining multiple treatment options because of variability in medication tolerability and patient response.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.References1: Tandem Diabetes Care. Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes. April 27, 2026. Accessed May 8, 2026. https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-cares-control-iq-automated-insulin-delivery2: Sanofi. Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children. April 22, 2026. Accessed May 8, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-32786503: Galindo RJ, Aronne LJ, Horn DB, et al. Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5. J Endocrinol Invest. Published online April 20, 2026. doi:10.1007/s40618-026-02895-3

01 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 02 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 03 - Travis Scott - FE!N (Rudeejay & Da Brozz Bootleg) 04 - BEAUZ & Cassie Ann - Dame Un Grr (Extended Mix) 05 - MilleniumKid x JBS - Vielleicht Vielleicht (Scotty Extended Mix) 06 - Bomfunk MC's - Freestyler (Matt Bukovski Cut) 07 - Kato feat Jon - Turn The Lights Off (BMzk Remix) 08 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 09 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 10 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 11 - Pogány Induló x Parno Graszt - Székelykapu (B00ST Hypertechno Remix) 12 - Eminem vs R3SPAWN - Without Me vs E (Josh Le Tissier Mashup) 13 - BLACKPINK - JUMP (Ray Techno Remix) 14 - ROSÉ & Bruno Mars - APT (Scotty Remix) 15 - Alice Deejay - Better Off Alone (Olly James Techno Rework) 16 - Sebastian Bronk - Everytime We Touch (Extended) 17 - Stephanie (HU) - What I've Done (Extended Mix) 18 - ACDC vs Dustin Zahn - Stranger To Thunderstruck (YuB & EDMMARO Techno Mix) 19 - Sebastian Bronk - L'Amour Toujours (Extended Version) 20 - BETON.HOFI & Hundred Sins - Bagira (Strong R. Remix) 21 - MO-DO - Eins Zwei Polizei (Jaydan Wolf & YuB Edit) 22 - R3SPAWN & Nia Mousai - Bad Romance (Extended Mix) 23 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 24 - Bassjackers - Around The World (La La La La La) (Extended Mix) 25 - DJ Kuba & Ne!tan x Terri B! with DJ Terry - Mr. Vain (Festival Cut) 26 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Remix) 27 - 50 Cent - In Da Club (RobxDan Extended Remix) 28 - John Summit - Lights Go Out (B00ST x HADEN Extended Remix) 29 - Dr. Dre & Snoop Dogg - The Next Episode (Josh Le Tissier Techno Remix) 30 - Gala - Freed from Desire (Kevin Kitchen Bootleg) 31 - Timmy Trumpet x Macklemore - Cant Hold Us x Freaks (Seb Barras Mashup) 32 - DESH & KKevin & Young Fly X Tiesto - Bandana X Free Your Mind (HADEN Mashup) 33 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Hyper Bootleg)

Discothèque Decadence Soundsystem presents DD021: Latin Yacht House Party A sun-drenched voyage through Latin house, yacht grooves, Balearic warmth, and feel-good dancefloor gold. Opening with the smooth luxury of Benny Santiago's “Give Me the Night - Cielo Extended”, the mix glides into The Doobie Brothers' “Long Train Runnin'”, Yacht Rock Revue's “San Junipero”, Daryl Hall & John Oates' “I Can't Go for That” in the Pomo remix, Party Pupils' “Never Too Much”, and Christopher Cross' “Ride Like The Wind - Yacht House Mix” — all bringing that glossy, sunset-on-the-water energy. Then the Latin fire rises. David Penn, DJ Chus & Dr. Kucho!'s “Esperanza” leads into Africanism & Salomão De Bahia's “Cada Vez”, before two personal weapons take centre stage: The Funk Assassin – “Sabor En Tu Piel” and The Funk Assassin – “Di Mi Nombre (Spanglish Pop Soul Edit)”. Both capture the heart of the mix: sensual, rhythmic, warm, and built for that golden-hour moment when the drinks are flowing, the sea is glowing, and the groove takes over. The second half goes full Latin house celebration with Los Amigos Invisibles & Masters At Work, Junior Jack, Basement Jaxx, Negrocan, Ultra Naté, Afro Medusa, Cesária Évora, and Bellini bringing carnival energy, percussion, big hooks, and Balearic heat. Latin house with yacht-house polish. Sunset cocktails. Big grooves. A Discothèque Decadence trip from the crates to the coastline. TRACKLIST 1. Benny Santiago - Give Me the Night Cielo Extended 2. The Doobie Brothers - Long Train Runnin' Full Guitar Mix 3. Platinum City - Rise 4. Lenny Kravitz, RedTop - Low RedTop Extended Remix 5. Yacht Rock Revue - San Junipero Every Night Like Tonight 6. Gaudi, Mr. Mister - Broken Wings Gaudi Rework 7. Daryl Hall & John Oates, Pomo - I Can't Go for That No Can Do Pomo Remix 8. Kenny Summit - Dirty Lowdown 9. That Needs An Edit - Pegged Back Original Mix 10. Party Pupils - Never Too Much 11. Saxity - Forget Me Nots 12. The Spinners - I'll Be Around Simp House Mix 13. Pete Le Freq - Boo Ghee Nites Original Mix 14. Gerry Rafferty, Heleno Vasquez - Baker Street Remix 15. Christopher Cross, Party Pupils - Ride Like the Wind Yacht House Mix 16. DJ Mark Brickman - I Keep Forgetting 17. George Benson, Back2Back - Turn Your Love Around Back2Back Remix 18. David Penn, DJ Chus, Dr. Kucho! - Esperanza Dr. Kucho Remix 19. Africanism, Salomé de Bahia - Cada vez Club Version 20. The Funk Assassin - Sabor En Tu Piel 21. Eric Kupper presents Organika - Malembe Avenida Extended 22. The Funk Assassin - Di Mi Nombre - Spanglish Pop Soul Edit 23. Los Amigos Invisibles, Masters At Work - Aurora Main Mix 24. Junior Jack - Bruja MAW Mix 25. Basement Jaxx, Cassie Watson, David Morales - E Samba Junior Jack Original Club Mix 26. Negrocan - Bingo Bango Latin Bango Mix 2021 Remaster 27. Todd Terry, Gypsymen, Copyright - Cada Vez Denis the Menace Mix 28. Ultra Naté, iitaly, Gregor Salto - Barbarabiri Copyright Remix 29. Daryl Hall & John Oates, Avangart Tabldot - Free Live Your Life iItaly & Gregor Salto Remix 30. Laurent Simeca, Stephan M - Out of Touch Avangart Tabldot Remix 31. Robin Rivera, Rhythm Bangers - Easy Lover 32. Afro Medusa, Knee Deep - Bang Bini & Martini's Exclusive Mix 33. Cesária Evora - Paixão Knee Deep Club Mix 34. Nicola Fasano, Pat Rich - Sangue de Beirona Main Pass By François K. 35. Bellini - 75 Brazil Street Vocal Mix 36. Bellini - Samba de Janeiro Club Mix

durée : 00:59:20 - par : Sébastien Llinares - Entre répertoire italien, français et quelques incursions germaniques, les albums " Consobrinae " d'Hermine Horiot et Giovanni Bellini et "Beyond Vivaldi" d'Evangelina Mascardi avec l'ensemble Estrovagante font un tour d'Europe du répertoire pour luth et théorbe, avec quelques pépites et raretés... - réalisation : Patrick Lérisset, Nelly Portal, Valentin Lévy-Chaudet Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

Day Break | Global Tensions, Domestic Power Struggles, and the Fight for America --- 00:00 - Monologue 19:00 – David A. Kallman, Senior Partner at the Kallman Legal Group. Kallman discusses a Minnesota public school proposal involving Muslim prayer rooms. He examines the legal and constitutional questions surrounding religious accommodation in public education. 27:49 – Scott Coburn, Chief Marketing Officer at Patriot Mobile. Coburn highlights Patriot Mobile's connectivity solutions tailored for values-driven and conservative-minded businesses. He explains how the company differentiates itself in the telecom space and directs listeners to patriotmobile.com using code GRUBER. 37:56 - Monologue Featuring Ivey Gruber 46:57 – Robert Bortins, CEO of Classical Conversations and author of Woke and Weaponized. Bortins discusses his book and the influence of ideological shifts in American education. He explains how classical, Christian homeschooling aims to offer an alternative approach. 57:02 – Ally Triolo, RNC Director of Election Integrity. Triolo discusses ongoing election integrity efforts, including developments surrounding redistricting in Virginia. She explains how these issues could impact future elections. 1:05:56 – Arnie Bellini, Chairman of ConnectSecure and technology investor. Bellini discusses the growing importance of AI security and the risks posed by bad actors using artificial intelligence. He emphasizes the need for investment in responsible AI education and infrastructure protection. 1:16:01 - Monologue 1:24:59 – Tom Coulson, owner of Liberty Coin Service. Coulson discusses current trends in precious metals and what investors should be watching. He also reviews listener coin submissions and invites more at https://youtu.be/p757dQjoydM

Rossini i Bellini s

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!On March 26, 2026, the US Food and Drug Administration (FDA) approved Novo Nordisk's insulin icodec-abae under the name Awiqli for patients with type 2 diabetes (T2D).1,2In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, highlight the FDA approval of once-weekly insulin icodec, emphasizing its significance as a major advancement in insulin therapy. They begin by addressing practical considerations, including its high concentration (U-700) and the implications for dosing, noting that weekly administration necessitates substantially higher unit doses compared with daily basal insulin.The discussion focuses on dosing strategy, particularly the need to scale weekly doses approximately sevenfold relative to daily regimens, as well as the rationale for an initial loading dose of 1.5 times the calculated weekly requirement to more rapidly achieve steady state. Isaacs underscores the pharmacokinetic basis for this approach, given the drug's long half-life and delayed time to steady state, while also noting the constraints of dosing in 10-unit increments.Bellini and Isaacs explore the clinical implications of once-weekly insulin, with particular attention to adherence and treatment burden. Bellini emphasizes the potential benefit for insulin-naive patients and those struggling with daily injection adherence, framing weekly insulin as a means to significantly reduce injection frequency and improve consistency. Isaacs expands on this, arguing that reduced dosing frequency may mitigate missed doses and glycemic variability, especially in patients with irregular routines. Both highlight the flexibility afforded by the long half-life, allowing for minor deviations in dosing timing without substantial impact on glycemic control.The conversation also addresses potential risks, including delayed titration and the possibility of over-basalization, particularly in patients with fluctuating nutritional intake or socioeconomic instability. They stress the importance of careful patient selection and monitoring, given the longer interval required to adjust doses.Reviewing clinical trial data from the ONWARDS phase 3 program, the hosts note that once-weekly insulin demonstrated modestly greater A1C reduction compared with daily basal insulin in treat-to-target trials, reinforcing the hypothesis that improved adherence may translate into better glycemic outcomes.They further discuss implementation considerations across care settings, highlighting potential advantages for older adults, caregivers, and patients in long-term care, where reduced injection burden may improve safety, independence, and medication management. The episode also touches on current regulatory limitations, noting that while approval is presently limited to type 2 diabetes in the United States, ongoing studies may expand its indication to type 1 diabetes, with off-label use anticipated in select cases.The hosts conclude by situating weekly insulin within the broader therapeutic landscape, emphasizing renewed innovation in insulin development alongside incretin-based therapies. They note that additional agents in development may soon expand options within this class, signaling a meaningful shift in the management of diabetes toward more patient-centered, lower-burden treatment paradigms.Editor's Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.References1: Novo Nordisk. Awiqli approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes. March 26, 2026. Accessed April 3, 2026. https://ml-eu.globenewswire.com/Resource/Download/cb9dda59-1286-4718-a7e5-4256e2397b0c2: Kunzmann K. FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes. HCPLive. March 26, 2026. Accessed April 3, 2026. https://www.hcplive.com/view/fda-approves-awiqli-insulin-icodec-first-once-weekly-basal-insulin-for-type-2-diabetes

01 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 02 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 03 - John Summit - Lights Go Out (B00ST x HADEN Extended Remix) 04 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 05 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 06 - Josh Le Tissier - Calabria (Techno Edit) 07 - 50 Cent - In Da Club (RobxDan Extended Remix) 08 - Kato feat Jon - Turn The Lights Off (BMzk Remix) 09 - Jaden Bojsen & David Guetta - Let's Go (Scotty Extended Mix) 10 - Travis Scott - FE!N (Rudeejay & Da Brozz Bootleg) 11 - Sebastian Bronk - Everytime We Touch (Extended) 12 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 13 - Usher - Yeah (NAEMS X Dirty Signal Bootleg Cut) 14 - Pogány Induló x Parno Graszt - Székelykapu (B00ST Hypertechno Remix) 15 - Eminem vs R3SPAWN - Without Me vs E (Josh Le Tissier Mashup) 16 - Alice Deejay - Better Off Alone (Olly James Techno Rework) 17 - Sebastian Bronk - L'Amour Toujours (Extended Version) 18 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 19 - Szecsei x Darwin feat Red Luna - My My My (Original Mix) 20 - MilleniumKid x JBS - Vielleicht Vielleicht (Scotty Extended Mix) 21 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Remix) 22 - Endor - Pump It Up (SHU Remix Edit) 23 - Creeds - Push Up (Szecsei & Dante Edit) 24 - BENNETT x Eurythmics - Vois Sur Ton Chemin x Sweet Dreams (Siks Edit) 25 - Gala - Freed from Desire (Kevin Kitchen Bootleg) 26 - Daddy Yankee - Gasolina (YuB x Szecsei Techno Cut) 27 - Swedish House Mafia feat Alicia Keys vs KAAZE feat Alina Pozi - Finally X PAPI (Aurelios & YuB Mashup) 28 - Sean Paul - Temperature (Denero Remix) 29 - Strong R. X Szecsei - Érezd A Ritmust (Extended Mix) 30 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Bootleg) 31 - Strong R. feat Adorján Anna - Kiskece (B00ST Remix)

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!On March 17, 2026, the American Association of Clinical Endocrinology (AACE) released a consensus statement, which features an algorithm for the management of type 2 diabetes (T2D) in adult patients.1In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, review the newly released 2026 American Association of Clinical Endocrinology (AACE) type 2 diabetes treatment algorithm, positioning it as an evolution of the 2023 update that integrates a growing body of clinical trial evidence into a more comprehensive, complications-focused framework. They emphasize a paradigm shift away from glucose-centric management alone, highlighting the importance of addressing comorbidities, including cardiovascular disease, chronic kidney disease, obesity, obstructive sleep apnea, and metabolic dysfunction–associated steatotic liver disease (MASLD), as central to optimizing outcomes.The discussion outlines the guideline's structure, including its 10 guiding principles, which reinforce lifestyle intervention as foundational, promote individualized glycemic targets (with a preference for A1c ≤6.5% when safely achievable), and strongly encourage early use of continuous glucose monitoring (CGM). The hosts underscore the emphasis on avoiding therapeutic inertia, minimizing hypoglycemia risk, and managing cardiometabolic comorbidities alongside glycemia as part of routine care.A key highlight is the introduction of a diabetes classification algorithm aimed at reducing misdiagnosis, particularly distinguishing type 1 from type 2 diabetes and identifying less common etiologies. Within this framework, the guidelines newly prioritize screening for hypercortisolism, informed by findings from the CATALYST trial, which demonstrated a higher-than-expected prevalence among patients with difficult-to-control diabetes. Isaacs and Bellini note that recognizing and treating underlying hypercortisolism may significantly improve glycemic control and, in some cases, reduce the need for diabetes-specific therapies.The episode further reviews updated algorithms for cardiovascular risk reduction, dyslipidemia, and hypertension, emphasizing aggressive, individualized targets and the continued central role of lifestyle modification. Pharmacologic recommendations reflect robust recent evidence, prioritizing SGLT2 inhibitors and GLP-1 receptor agonists (including dual GIP/GLP-1 agents) for patients with cardiorenal or metabolic comorbidities, while also incorporating emerging indications such as heart failure with preserved ejection fraction and MASLD.Isaacs and Bellini also discuss the guideline's glucose-centric algorithm for patients without major comorbidities, highlighting patient-centered decision-making based on factors such as hypoglycemia risk, weight considerations, and cost/access. They reinforce recommendations for early combination therapy when A1c is significantly above target and appropriate use of insulin, including guidance on avoiding overbasalization and incorporating prandial strategies.The conversation concludes with commentary on the guideline's practical strengths, including clear visual algorithms, concise format, and detailed pharmacotherapy tables summarizing efficacy, safety, and organ-specific benefits. The hosts emphasize that the updated AACE algorithm provides clinicians with an actionable, evidence-based roadmap for delivering holistic, individualized diabetes care that extends beyond glycemic control to address the full spectrum of cardiometabolic risk.Editor's Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.ReferencesSamson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes - 2026 Update. Endocr Pract. Published online March 17, 2026. doi:10.1016/j.eprac.2026.01.006

Gaetano Donizetti was one of Italy's most prolific tunesmiths, with almost 70 operas to his name – about as many as Rossini, Bellini and Verdi all combined - whose arias still cut straight to the heart today. Donald Macleod follows his irresistible rise: from a child brought up in a dark, cramped cellar to become a pioneering master of the style known as bel canto. And like any opera plot, there's triumph and tragedy, headaches and heartbreak…Music featured: L'Elisir d'amore Gloria (from Messa di Gloria) String Quartet No 5 in E minor Waltz in G major Zoraida Amor marinaro L'Esule di Roma Lucrezia Borgia Lucia di Lammermoor String Quartet No 16 Maria Stuarda Messa di Requiem ll sogno “Nostre misere menti” Il sospiro “Donna felice, stanca d'amore” Poliuto La fille du regiment Les Martyrs La fille du regiment Maria Padilla Trovatella “Sovra il campo della vita” Don Pasquale String Quartet No 18 Dom Sebastien: Seul sur la terre Requiem: Offertorio – Lux AeternaProduced by Amelia Parker for BBC Audio Wales and West.For full track listings, including artist and recording details, and to listen to the pieces featured in full (for 30 days after broadcast) head to the series page for Gaetano Donizetti (1797-1848): https://www.bbc.co.uk/programmes/m002sd9nAnd you can delve into the A-Z of all the composers we've featured on Composer of the Week here: http://www.bbc.co.uk/programmes/articles/3cjHdZlXwL7W41XGB77X3S0/composers-a-to-z

A cura di Paolo PellegriniVincenzo Bellini, I PuritaniElvira, Joan Sutherland (soprano)Lord Arturo Talbot, Gianni Raimondi (tenore)Sir Riccardo Forth, Mario Zanasi (baritono)Sir Giorgio, Ferruccio Mazzoli (basso)Enrichetta di Francia, Vera Magrini (mezzosoprano)Lord Gualtiero Valton, Antonio Zerbini (basso)Sir Bruno Robertson, Mario Ferrara (tenore)Coro e Orchestra del Teatro Massimo di PalermoTullio Serafin, direttore

Vasilisa Berzhanskaya Dmitry Korchak Teatro Regio di Parma February 2026 In-house

Sheldon Papp x Chasey LIVE @ Bellini The Cruise by Dj Sheldon Papp

A cura di Paolo PellegriniVincenzo Bellini, NormaNorma, Maria CallasPollione, Mario Del MonacoAdalgisa, Ebe StignaniOroveso, Giuseppe ModestiClotilde, Rina CavallariFlavio, Athos CesariniOrchestra Sinfonica e Coro della RAI di RomaTullio Serafin, direttore

A cura di Paolo PellegriniVincenzo Bellini, La sonnambulaAmina, Joan SutherlandElvino, Nicolai GeddaRodolfo, Giorgio TozziLisa, Jeanette ScovottiTeresa, Gladys KrieseAlessio, Louis SgarroNotaio, Arthur GrahamCoro e Orchestra del Metropolitan Opera di New YorkSilvio Varviso, direttore

Today's Black History Month episode serves also as a belated birthday tribute to the exceptional African American soprano Faye Robinson, who was born in Houston on 2 November 1943. Robinson has a voice that transcends genre, encompassing both lyric-coloratura roles at one end and pure dramatic soprano repertoire on the other. In addition, she has been created vocal works by some of the greatest twentieth-century composers, including Michael Tippett, two of whose major vocal works she premiered, and with whose compositions she is especially associated, and George Walker, whose Lilacs she premiered in 1996 with the Boston Symphony Orchestra, and which subsequently won the 1996 Pulitzer Prize by the judges' unanimous decision. Robinson's immediately recognizable voice presented in a wide-range of repertoire, including the works referenced above and also including arias by Handel, Gounod, Offenbach, Bellini, and Handel, as well as the Chevalier de Saint-Georges; as well as concert work by Schoenberg and Barber. All in all, Faye Robinson's is a voice and artistic presence well worth getting to know better! Happy Belated Birthday, Diva! Countermelody is the podcast devoted to the glory and the power of the human voice raised in song. Singer and vocal aficionado Daniel Gundlach explores great singers of the past and present focusing in particular on those who are less well-remembered today than they should be. Daniel's lifetime in music as a professional countertenor, pianist, vocal coach, voice teacher, and author yields an exciting array of anecdotes, impressions, and “inside stories.” At Countermelody's core is the celebration of great singers of all stripes, their instruments, and the connection they make to the words they sing. By clicking on the following link (https://linktr.ee/CountermelodyPodcast) you can find the dedicated Countermelody website which contains additional content including artist photos and episode setlists. The link will also take you to Countermelody's Patreon page, where you can pledge your monthly or yearly support at whatever level you can afford.

01 - Andrewboy & Szecsei feat Kinga Peterfy - Kiskece 2016 (Strong R. Intro Version) 02 - Rico x Miss Mood - Vihar (Dj Free & Purebeat Remix) 03 - G & G - Personal Jesus (Jackwell & Szecsei Remix) 04 - Tomcraft - Like A Roller (Jackwell & Field Bootleg) 05 - Jose Delgado - Virginn (Jackwell & Szecsei Edit) 06 - Andrewboy feat Timi Szegedi - No More Silence (Jackwell & Szecsei Remix) 07 - Tiesto & Sevenn - BOOM (Jackwell & Szecsei Bootleg) 08 - Diplo feat SIDEPIECE - On My Mind (Jackwell Bootleg) 09 - Eminem x Inndrive - Without Me (Jackwell Edit) 10 - Icona Pop feat Charlie XCX - I Love It (Jackwell Edit) 11 - Joel Corry x Sidney Samson x Pajane - Riverside MF (Jackwell Edit) 12 - Endor - Pump It Up (TAZI Edit) 13 - Pitbull - Hotel Room Service (ANASTOVSKII Edit) 14 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Bootleg) 15 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 16 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 17 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 18 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 19 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 20 - Sebastian Bronk - Everytime We Touch (Extended) 21 - Gigi D'Agostino - Bla Bla Bla (Fahjah x Jesyka Nu Groove Remix) 22 - Alice Deejay - Better Off Alone (Olly James Techno Rework) 23 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 24 - DJ Kuba & Ne!tan x Terri B! with DJ Terry - Mr. Vain (Festival Cut) 25 - Pogány Induló x Parno Graszt - Székelykapu (B00ST Hypertechno Remix) 26 - Sebastian Bronk - L'Amour Toujours (Extended Version) 27 - Szecsei x Darwin feat Red Luna - My My My (Original Mix) 28 - MO-DO - Eins Zwei Polizei (Jaydan Wolf & YuB Edit) 29 - R3SPAWN & Nia Mousai - Bad Romance (Extended Mix) 30 - 50 Cent - In Da Club (RobxDan Extended Remix) 31 - Jaden Bojsen & David Guetta - Let's Go (Scotty Extended Mix) 32 - La Bouche - Be My Lover (ThnderZ x Lupage x Teddy Cream RaveTok Cut) 33 - David Guetta & OneRepublic - I Don't Wanna Wait (Hardwell & Olly James Cut) 34 - Kato feat Jon - Turn The Lights Off (BMzk Remix) 35 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Remix) 36 - Bassjackers - Around The World (La La La La La) (Extended Mix) 37 - Creeds - Push Up (Szecsei & Dante Edit) 38 - ROSÉ & Bruno Mars - APT (Scotty Remix) 39 - Daddy Yankee - Gasolina (YuB x Szecsei Techno Cut) 40 - Swedish House Mafia feat Alicia Keys vs KAAZE feat Alina Pozi - Finally X PAPI (Aurelios & YuB Mashup) 41 - Gala - Freed from Desire (Kevin Kitchen Bootleg) 42 - SNAP - Rhythm Is A Dancer (Orkestrated vs HEY SIRI Edit) 43 - Darude - Sandstorm x Miracle (LEVEL UP 2K23 Mash Up Mix) 44 - Azahriah és DESH X Steve Angello - Mind1 X Knas 2024 (HADEN Mashup) 45 - T. Danny - Megmondtam (Jauri Remix) 46 - Strong R. feat Adorján Anna - Kiskece (B00ST Remix)

01 - Andrewboy & Szecsei feat Kinga Peterfy - Kiskece 2016 (Strong R. Intro Version) 02 - Rico x Miss Mood - Vihar (Dj Free & Purebeat Remix) 03 - Jamie Woon - Shoulda (Purebeat Special After Remix) 04 - G & G - Personal Jesus (Jackwell & Szecsei Remix) 05 - Tomcraft - Like A Roller (Jackwell & Field Bootleg) 06 - Timmy Trumpet x Macklemore - Cant Hold Us x Freaks (Seb Barras Mashup) 07 - Ricchi e Poveri - Sarà Perché Ti Amo (Szecsei & Darwin Bootleg) 08 - HADEN x Szecsei - Cherokee 2025 (Intro Version) 09 - DESH X Young Fly X Azahriah - PANNONIA (CrazyBoys Remix) 10 - Bellini x Matty Ralph - Samba Do Brasil x No Whistle, No Party (Rudeejay & Da Brozz x EDMMARO Mashup) 11 - Jaxomy x Agatino Romero x Raffaella Carrà - Pedro (Szecsei x Thomas Rush Edit) 12 - MilleniumKid x JBS - Vielleicht Vielleicht (Scotty Extended Mix) 13 - Skrillex & Habstrakt - Chicken Soup (HADEN X Szecsei Remix) 14 - MO-DO - Eins Zwei Polizei (Jaydan Wolf & YuB Edit) 15 - Bassjackers - Around The World (La La La La La) (Extended Mix) 16 - Ice Mc - Think About The Way (Kyros Remix) 17 - DJ Kuba & Ne!tan x Terri B! with DJ Terry - Mr. Vain (Festival Cut) 18 - Pogány Induló x Parno Graszt - Székelykapu (B00ST Hypertechno Remix) 19 - Eminem vs R3SPAWN - Without Me vs E (Josh Le Tissier Mashup) 20 - R3SPAWN X Milan Gavris feat ExtraGirl - Because The Night (Extended Mix) 21 - Sebastian Bronk - Everytime We Touch (Extended) 22 - 50 Cent - In Da Club (RobxDan Extended Remix) 23 - RobxDan & Consilium - Maria (I Like It Loud) (Extended Mix) 24 - David Guetta & OneRepublic - I Don't Wanna Wait (Hardwell & Olly James Cut) 25 - Kato feat Jon - Turn The Lights Off (SCOTTY Remix) 26 - Szecsei x Darwin feat Red Luna - My My My (Original Mix) 27 - Creeds - Push Up (Szecsei & Dante Edit) 28 - Gigi D'Agostino - Bla Bla Bla (Fahjah x Jesyka Nu Groove Remix) 29 - Fedde Le Grand & Funkerman feat Dorothy & Andy Sherman - 3 Minutes To Explain (Original Mix) 30 - Run DMC vs Jason Nevins - It's Like That (Raxon vs B-Sensual Mix) 31 - Offer Nissim feat Maya - First Time (Jackwell & Field Bootleg) 32 - Ron Carroll - Bump To This (Muzzaik Remix) 33 - A-Studio feat Polina - S.O.S. 2024 (B-Sensual Mix) 34 - D. Ramirez & Mark Knight & Underworld - Downpipe (Original Club Mix) 35 - Sarah McLeod - He Doesn't Love You (B-Sensual Bootleg) 36 - Delerium & Sarah McLachlan - Silence '08 (Niels Van Gogh & Thomas Gold Remix) 37 - Fragma - Toca's Miracle (Inpetto 2008 Vocal Remix) 38 - Robin S vs Steve Angello & Laidback Luke - Show Me Love vs Be (Extended) 39 - Paul Kalkbrenner - Sky & Sand (Koen Groeneveld Bootleg) 40 - Radio Slave feat Danton Eeprom - Grindhouse (Johnes & Szecsei 2016 Edit) 41 - Jose Delgado - Virginn (Jackwell & Szecsei Edit) 42 - Andrewboy feat Timi Szegedi - No More Silence (Jackwell & Szecsei Remix) 43 - KatapultDJ AllSTARs - Meg Kell Inni (Jackwell & Szecsei Edit) 44 - Strong R. X Szecsei - Érezd A Ritmust (Extended Mix) 45 - Strong R. feat Adorján Anna - Kiskece (B00ST Remix)

Afro Latino Winter 3 @ DJ Глюк 1. SGX, Dave Ruthwell - Você Vai Vai (Original Mix) 2. Dario Nuñez, Bubba Brothers - Deeper (Original Mix) 3. ARKAD3 - Finder House (Extended Mix) 4. James Hurr, Jay Rah - Pinta La Cara (Extended Mix) 5. Richard Grey & Lissat - Somebody Dance (Funky Tribal Mix) 6. Richard Grey - Show Me Love (Final Afro Mix) 7. Nari - Latinos (Original Mix) 8. All Fred - El Sol (Extended Mix) 9. Bellini, Harald Matthias, Vin Vega - Carnaval (Extended Mix) 10. Gerardo Corona - Zavor (Original Mix) 11. Nausica, Salvatore Papa - Me Rebota (Extended Version) 12. Carlos Agraz - Lokoss (Extended Mix) 13. Erick Cz, Mr Ed (MX) - Meneito (Original Mix) 14. Walter Gardini - Lamor (Original Mix) 15. Funkera - Del Mariachi (Extended Mix)

The Steve Gruber Show | Common Sense Then, ‘Extremism' Now --- 0:00:00 - Hour 1 Monologue 18:55 – Carrie Sheffield, Senior Policy Analyst at the Independent Women's Forum. Sheffield reacts to President Trump's Michigan speech and the defense of his economic strategy. She explains how his message is resonating with voters amid ongoing economic uncertainty. 27:50 – Dr. Alejandro Diaz, Chief of Pediatric Medicine at The Wellness Company. Dr. Diaz discusses RFK Jr.'s efforts to “Make America Healthy Again” and the broader push for medical transparency and patient-first care. Visit twc.health/GRUBER and use promo code GRUBER to save 10%. 38:01 - Hour 2 Monologue 46:40 – Arnie Bellini, cybersecurity CEO and multimillionaire founder of a cybersecurity school. Bellini analyzes escalating deadly protests in Iran and how Chinese technology is being used to launch cyberattacks on Starlink satellites. He explains what this means for global security and U.S. infrastructure. 56:44 – Susan Kokinda, author and organizer with Promethean Action. Kokinda argues that Trump 's visit to the World Economic Forum in Davos isn't about negotiation. Instead, she says he's delivering terms of surrender to global elites. 1:05:41 – Kris Ullman, President of Eagle Forum. Ullman outlines why there should be no flexibility when it comes to taxpayer funding of abortion. She discusses the legal, moral, and fiscal arguments behind Eagle Forum's stance. 1:15:29 - Hour 3 Monologue 1:24:16 – Ron Rademacher, founder of Michigan Back Roads. Rademacher highlights upcoming events and destinations across the state of Michigan. He shares ideas for exploring local history, outdoor adventures, and community gatherings. Visit michiganbackroads.com. 1:34:07 – State Rep. Mark Tisdel, R–Rochester Hills, representing Michigan's 55th District. Rep. Tisdel explains his legislation aimed at keeping cellphones out of classrooms. He discusses how the bill would improve focus, learning, and student well-being. 1:43:01 – Ivey Gruber, President of the Michigan Talk Network. Gruber provides an update from the Supreme Court on efforts to keep men out of women's sports. They discuss the broader legal and cultural implications of the court's actions. --- Visit Steve's website: https://stevegruber.com TikTok: https://www.tiktok.com/@stevegrubershow Truth: https://truthsocial.com/@stevegrubershow Gettr: https://gettr.com/user/stevegruber Facebook: https://www.facebook.com/stevegrubershow Instagram: https://www.instagram.com/stevegrubershow/ Twitter: https://twitter.com/Stevegrubershow Rumble: https://rumble.com/user/TheSteveGruberShow  

Matt and EzRaw announce the 2025 Bellini Award winners.Read the latest news at Brunch BoxingThoughts or questions? Email us at brunchboxingqa@gmail.comHosts: Matt, and EzRawSocial: MikeProducer: Huey

News and Notes- Teofimo Lopez vs. Shakur Stevenson kickoff presser: - Keyshawn Davis pulls up on Richardson Hitchins.- Pitbull Cruz moving on from Lamont Roach.- Devin Haney would like to fight Gervonta Davis in 2026, according to Bill Haney.- Canelo Alvarez will not fight on Cinco de Mayo weekend. He will aim for a September rematch against Terence Crawford.EZ Money Parlay of the Day, EzRaw Report Card, EzRaw Breakdown- EzRaw Breakdown and Report Card: Today's boxing events- Matt's Best Bet.Booking the Territory: Bellini Nominations 2025Quick Hits- The bout between Mike Tyson and Floyd Mayweather will take place in Africa in March, according to Tyson. - Shields To Face Crews-Dezurn In Huge Grudge Match,Read the latest news at Brunch BoxingThoughts or questions? Email us at brunchboxingqa@gmail.comHosts: Matt, and EzRawSocial: MikeProducer: Huey

In this special episode, we're joined once again by two extraordinary figures in the world of opera, mezzo-soprano Frederica von Stade, affectionately known as Flicka, and composer Jake Heggie. Flicka has graced the great opera houses and concert halls for over four decades, known for her captivating performances in roles by Rossini and Bellini, as well as her powerful interpretations of modern works like Heggie's own operas, including Dead Man Walking. Jake is renowned for his operas, having created over ten full-length works, including the widely acclaimed Moby-Dick and, of course, Dead Man Walking.In Part 1, we delve into their creative partnership, particularly focusing on their song cycle Paper Wings, inspired by Flicka's children. They share personal stories about the songs that resonate universally, illustrating how specific experiences can lead to broader emotional connections in art. The discussion also touches on the joy of collaborating and the importance of maintaining humor in their performances.[Subscriber Content] In Part 2, Jake and Flicka reveal more about their personal journeys with music and performance, including the importance of pushing through those dreaded "bad days" where things just don't seem to work right. Flicka discusses the emotional depth in her interpretations, while Jake reflects on the significance of trust in music. Their insights provide a deeper understanding of the art of singing, composing, and music in general enriching the listener's appreciation for the nuances of opera and lyrical storytelling. Listen in for a heartwarming conversation filled with memories, laughter, and profound insights into the world of music and creativity.Would you like more inspirational stories, suggestions, insights, and a place to continue the conversations with other listeners? Visit anthonyplog-on-music.supercast.com to learn more! As a Contributing Listener of "Anthony Plog on Music," you'll have access to extra premium content and benefits including: Extra Audio Content: Only available to Contributing Listeners. Podcast Reflections: Tony's written recaps and thoughts on past interviews, including valuable tips and suggestions for students. Ask Me Anything: Both as written messages and occasional member-only Zoom sessions. The Show's Discord Server: Where conversations about interviews, show suggestions, and questions happen. It's a great place to meet other listeners and chat about all things music! Can I just donate instead of subscribing? Absolutely! Cancel at anytime and easily resubscribe when you want all that extra content again. Learn more about becoming a Contributing Listener @ anthonyplog-on-music.supercast.com!

Casta diva, prima donna, Maria Callas. Fully available for Supporter Club members only. Credits :  “Aida (Preludio)” by G. Verdi (1871)  -  “Norma (Cavatina)” by V. Bellini (1831)  -  “Tosca (Atto II)” by G. Puccini (1900)Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/pillole-di-italiano--4214375/support.

In this episode of Tank Talks, host Matt Cohen sits down with Roberto Bellini, Co-Founder of BSQUARED Capital and former CEO of Bellus Health, for a powerful conversation about family, legacy, and resilience in the world of biotech.Originally recorded just two weeks before the passing of his father, Dr. Francesco Bellini, one of the founding giants of Canadian biotech, this re-recorded episode serves as a moving tribute to the man known as “Mr. Biotech Canada.” Roberto opens up about what it was like growing up under the guidance of such a visionary figure and how that experience shaped his own path as an entrepreneur and leader.He reflects on the highs and lows of leading Bellus Health, from moments of near collapse to its remarkable $2 billion acquisition by GSK, sharing lessons on risk-taking, perseverance, and the importance of staying grounded through uncertainty. Roberto also offers his perspective on the future of Canadian biotech, highlighting the need for stronger late-stage funding and how BSquared Capital is helping to cultivate the next generation of innovators.This episode isn't just about business success; it's about honoring a legacy, learning through adversity, and discovering what it truly means to build something that endures.The Legacy of Dr. Francesco Bellini (00:02:52)* Francesco Bellini's incredible immigrant story: from arriving in Canada with nothing to a $6B biotech exit.* Business was the family's dinner table conversation, and attending AGMs as a child.* The founding of Biochem Pharma and the discovery of the groundbreaking HIV treatment.* “He was a visionary... he saw things before other people saw them.”Growing Up in Biotech (00:06:30)* Roberto's early memories of board meetings and dinner-table business lessons* How being “in the room” shaped his entrepreneurial mindset* Watching a $6B biotech deal become part of family historyThe Rise, Fall, and Rebirth of Bellus Health (00:08:27)* Roberto's journey from family office analyst to a 30-year-old, first-time CEO of a public company.* The devastating failure of the phase three trial for a rare kidney disease.* Inside a Biotech Failure: The intense, weekend-long “war room” process of unblinding clinical trial data and preparing for a public announcement.The Second Act: Finding the Cough Drug (00:13:47)* Discovering a promising molecule through the NeoMed Institute* Betting the company's future on a last-chance asset* Raising $20M when no one believed and turning it into a $2B successNegotiating the GSK Deal (00:24:45)* The strategic shift from “build-to-sell” to “build-to-scale”, positioning the company for a premium acquisition.* The M&A Playbook: Why you should never lead with a desire to sell; the importance of building for independence.* The high-stakes negotiation with GSK: going from an $11 offer to $14.75, almost losing the deal, and the “mellow tone” that saved it.* The entrepreneur's dilemma: “Every single entrepreneur I've met that sold their company, there's always a moment of not wanting to do it.”Building Canada's Biotech Future (00:30:11)* Why Canada has the innovation but lacks the enduring biotech giants.* The critical gap: The need for more late-stage capital and the role of Canadian pension funds.* The “Gilead of the North” vision: Creating a virtuous cycle of capital, entrepreneurs, and translational science.* Upcoming trends: The convergence of AI and drug discovery to de-risk development and lower costs.Beyond the Lab: Leadership, Risk, and Legacy (00:46:20)* Learning to embrace risk and find joy in reinvention* The best advice from Dr. B: “Spend your money, it'll make you want to earn more.”* Why true success isn't just building a company, but building peopleAbout Roberto BelliniFounder & Managing Partner, BSQUARED CapitalRoberto Bellini is a second-generation biotech entrepreneur and investor. As the former CEO of Bellus Health, he led the company's dramatic turnaround and eventual $2 billion acquisition by GSK. Drawing on his deep operational experience in drug development, he now co-manages BSQUARED Capital, a family office focused on investing in and supporting promising biotech ventures. He is a passionate advocate for building a stronger, more resilient biotech ecosystem in Canada.Connect with Roberto Bellini on LinkedIn: https://www.linkedin.com/in/robertobellini/Visit BSQUARED Capital Website: https://bsq-c.com/Connect with Matt Cohen on LinkedIn: https://ca.linkedin.com/in/matt-cohen1Visit the Ripple Ventures website: https://www.rippleventures.com/ This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit tanktalks.substack.com

Daily Dose of Hope October 31, 2025 Scripture – John 13:18-38 Prayer: Abba Father, We come to you today, grateful for your love and care in our lives. Thank you for your presence and your peace. Help us to gather our scattered thoughts and set aside distractions so we can focus on what you have for us today. In the next few moments of silence, Lord, help me be still and know that you are God...We give you all the glory, Lord Almighty. Amen. Welcome back to the Daily Dose of Hope, the devotional and podcast that complements the New Hope Church Bible reading plan. As most of you know, we have been going through the Gospels and Acts. Today, we finish up John 13. In John's Gospel, there is an extended text about Jesus predicting Judas' betrayal. When asked who will be the one to betray him, Jesus says the one he dips the bread and offers it to. Jesus then dips the bread and gives it to Judas. He tells Judas to do what he is going to do and do it quickly. I often wondered why the disciples didn't notice this interaction more. They seem someone oblivious and lost in their own thoughts. Maybe they each wondered if they could be the one to betray their Master? John writes of a point in which Judas allows Satan to enter him. He had previously been influenced by Satan but now he has allowed the devil to have his way with him. At first, he opened the door a little. Then, he just opened the door wide. The devil had been feeding him lies, and Judas started believing them, totally and completely. The devil tempted him with money, and Judas found 30 pieces of silver more valuable than the God. Jesus told Judas that joy was to be found in sacrificially serving others, but Judas believed that Satan's way of putting self first was better. We recently went to a clergy training on deliverance, led by Pete Bellini, a professor at United Seminary in Dayton, Ohio. It was absolutely incredible and I would highly recommend Dr. Bellini's books. But one of the things that Dr. Bellini said was that we as Christ-followers cannot be possessed by Satan. We belong to Jesus so we can never totally belong to Satan. But we can become oppressed. We can open the door to the demonic through various means, i.e. porn use, messing with occult-related activities, and when we do so, demons can attach themselves to us. Satan can oppress certain parts of us. We may not even be aware of it. That is when deliverance is necessary. So, was Judas possessed or oppressed? Did he know Jesus? Did he believe? I don't know if we will ever know this side of heaven. Most of the scholars I read said they thought he was totally possessed by Satan at the end. Who knows? I would love your thoughts. Let's move on in our passage. Verses 34 and 35 are really incredible, A new command I give you: Love one another. As I have loved you, so you must love one another. 35 By this everyone will know that you are my disciples, if you love one another." It's as if, in two sentences, Jesus has summarized all his teachings to his disciples. And they aren't easy because they center on how we love one another. If we were to take these verses and look at church history, we would wonder if we were looking at the same faith. Christian history has done horrific things in Jesus' name. I think he must weep and mourn at this. Everything Jesus did was about teaching others to love and serve each other. And somehow, this got terribly corrupted. As we keep reading, Peter makes a very bold, ambitious claim that even if everyone else fell away and disappeared, he would not. Jesus doesn't mince words. He tells Peter that he will betray Jesus three times by that night (or as the text says, by the time the rooster crows two times). But Peter, and all the others, insist that they will follow Jesus even until death. I've thought about this a lot. At this time, the disciples still don't understand Jesus' ministry or purpose. They think they will follow him no matter what but we know what happens. They all scatter once Jesus is arrested. Peter does deny him three times in just a few short hours, consumed with fear for his own safety. When push came to shove, they weren't quite as invested in Jesus' mission as they thought. But then things changed. After the resurrection, the disciples were changed in fundamental ways. Peter, who was initially impulsive and fearful, becomes strong and bold, a superb leader in the early church. After experiencing both the risen Lord and the power of the Holy Spirit, their whole outlook on life is transformed. And all of them, except for John, are martyred for the Gospel. They do end up following Jesus to their own earthly death, just not in the timing they expected. I've asked this question before but it's worth repeating - would you follow Jesus to the point of giving up your life? If you were being tortured and persecuted for your faith, would you stay faithful to Jesus or would you give in to the pressure and deny Christ? It is not outside the realm of possibility that such a situation could exist for us. Afterall, it does exist for Christians all over the world. Reflect on this and spend some time in prayer. Blessings, Pastor Vicki

This episode is about songs of the heart. There is one from Russia, performed two different ways. (That song is by a man named Tolstoy, although not the author of those great novels.) There is one from Samoa. This episode contains assorted treasures—not the least of them by J. S. Bach. Bellini, Excerpt from “La sonnambula” Bellini, Excerpt from “La sonnambula” Bach, Fugue in G major, BWV 577 Bach, “Liebster Jesu,” BWV 731 Tolstoy-Lim, “On This Quiet Summer Night” Tolstoy, “On This Quiet Summer Night” Trad., “La'u Lupe”

Dave speaks with Anna Bellini, an alum of the Coaching for Leaders Academy, on how to stop a behavior in order to move forward. Applications to the Coaching for Leaders Academy will open the first week of September. Visit the Academy page to request an early invitation.